The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis

REFERENCES

• Bringardner BD, Baran CP, Eubank TD, Marsh CB: The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Sign. 2008;10(2):287–301.
   PubMed Web of Science ®Google Scholar
• McGrath EE, Millar AB: Hot off the breath: triple therapy for idiopathic pulmonary fibrosis–hear the PANTHER roar. Thorax. 2012;67(2):97–98.
   PubMed Web of Science ®Google Scholar
• Adamali HI, Maher TM: Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Dev Ther. 2012;6:261–272.
   PubMed Web of Science ®Google Scholar
• Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D: Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev: Official J Eur Resp Soc. 2012;21(126):355–361.
   Google Scholar
• Dempsey OJ, Kerr KM, Gomersall L, Remmen H, Currie GP: Idiopathic pulmonary fibrosis: an update. QJM: Monthly J Assoc Phys. 2006;99(10):643–654.
   PubMed Web of Science ®Google Scholar
• Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU: The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;166(2):173–177.
   PubMed Web of Science ®Google Scholar
• Harari S, Caminati A: Idiopathic pulmonary fibrosis. Allergy. 2005;60(4):421–435.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Jr., Raghu G: Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–2101.
   PubMed Web of Science ®Google Scholar
• King TE, Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al.: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al.: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA: Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol. 1979;95(1):117–130.
   PubMed Web of Science ®Google Scholar
• Snider GL, Celli BR, Goldstein RH, O'Brien JJ, Lucey EC: Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Lung volumes, volume-pressure relations, carbon monoxide uptake, and arterial blood gas studied. Am Rev Respir Dis. 1978;117(2):289–297.
   PubMed Web of Science ®Google Scholar
• Borzone G, Moreno R, Urrea R, Meneses M, Oyarzun M, Lisboa C: Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7):1648–1653.
   PubMed Web of Science ®Google Scholar
• Umezawa H, Maeda K, Takeuchi T, Okami Y: New antibiotics, bleomycin A and B. J Antibiot. 1966;19(5):200–209.
   PubMed Web of Science ®Google Scholar
• Umezawa H, Takeuchi T, Hori S, Sawa T, Ishizuka M: Studies on the mechanism of antitumor effect of bleomycin of squamous cell carcinoma. J Antibiot. 1972;25(7):409–420.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Miyake H, Sakai M, Inuyama Y, Matsukawa J: Bleomycin in malignant tumors of head and neck. Keio J Med. 1969;18(3):153–162.
   PubMedGoogle Scholar
• Samuels ML, Johnson DE, Holoye PY: Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep Part 1. 1975;59(3):563–570.
   PubMedGoogle Scholar
• Schein PS, DeVita VT, Jr., Hubbard S, Chabner BA, Canellos GP, Berard C, et al.: Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med. 1976;85(4):417–422.
   PubMed Web of Science ®Google Scholar
• O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A: Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol: Offic J Eur Soc Med Oncol/ESMO. 2003;14(1):91–96.
   Web of Science ®Google Scholar
• Cancer CSC-OGotEOfRotTo: Study of the clinical efficiency of bleomycin in human cancer. Brit Med J. 1970;2(5710):643–645.
   PubMed Web of Science ®Google Scholar
• Halnan KE, Bleehen NM, Brewin TB, Deeley TJ, Harrison DF, Howland C, et al.: Early clinical experience with bleomycin in the United Kingdom in series of 105 patients. Brit Med J. 1972;4(5841):635–638.
   PubMed Web of Science ®Google Scholar
• Huang CH, Mirabelli CK, Jan Y, Crooke ST: Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues. Biochemistry. 1981;20(2):233–238.
   PubMed Web of Science ®Google Scholar
• Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM: The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Brit J Cancer. 2001;84(9):1272–1279.
   PubMed Web of Science ®Google Scholar
• Tounekti O, Pron G, Belehradek J, Jr., Mir LM: Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res. 1993;53(22):5462–5469.
   PubMed Web of Science ®Google Scholar
• Sugiura Y, Kikuchi T: Formation of superoxide and hydroxy radicals in iron(II)-bleomycin-oxygen system: electron spin resonance detection by spin trapping. J Antibiot. 1978;31(12):1310–1312.
   PubMed Web of Science ®Google Scholar
• Sausville EA, Peisach J, Horwitz SB: Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry. 1978;17(14):2740–2746.
   PubMed Web of Science ®Google Scholar
• Rodriguez LO, Hecht SM: Iron(II)-bleomycin. Biochemical and spectral properties in the presence of radical scavengers. Biochem Biophys Res Commun. 1982;104(4):1470–1476.
   PubMed Web of Science ®Google Scholar
• Liu LV, Bell CB, 3rd, Wong SD, Wilson SA, Kwak Y, Chow MS, et al.: Definition of the intermediates and mechanism of the anticancer drug bleomycin using nuclear resonance vibrational spectroscopy and related methods. Proc Natl Acad Sci USA. 2010;107(52):22419–22424.
   PubMed Web of Science ®Google Scholar
• Decker A, Chow MS, Kemsley JN, Lehnert N, Solomon EI: Direct hydrogen-atom abstraction by activated bleomycin: an experimental and computational study. J Am Chem Soc. 2006;128(14):4719–4733.
   PubMed Web of Science ®Google Scholar
• Hecht SM: Bleomycin: new perspectives on the mechanism of action. J Nat Prod. 2000;63(1):158–168.
   PubMed Web of Science ®Google Scholar
• Pogozelski WK, Tullius TD: Oxidative strand scission of nucleic acids: routes initiated by hydrogen abstraction from the sugar moiety. Chem Rev. 1998;98(3):1089–1108.
   PubMed Web of Science ®Google Scholar
• Burger RM: Cleavage of nucleic acids by bleomycin. Chem Rev. 1998;98(3):1153–1170.
   PubMed Web of Science ®Google Scholar
• Pron G, Belehradek J, Jr., Mir LM: Identification of a plasma membrane protein that specifically binds bleomycin. Biochem Biophys Res Commun. 1993;194(1):333–337.
   PubMed Web of Science ®Google Scholar
• Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J, Jr., et al.: Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol. 1999;57(1):45–56.
   PubMed Web of Science ®Google Scholar
• Aouida M, Poulin R, Ramotar D: The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010;285(9):6275–6284.
   PubMed Web of Science ®Google Scholar
• Lefterov IM, Koldamova RP, King J, Lazo JS: The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage. Mutat Res. 1998;421(1):1–7.
   PubMed Web of Science ®Google Scholar
• Lazo JS, Humphreys CJ: Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci USA. 1983;80(10):3064–3068.
   PubMed Web of Science ®Google Scholar
• Bromme D, Rossi AB, Smeekens SP, Anderson DC, Payan DG: Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochemistry. 1996;35(21):6706–6714.
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Velasco G, Campo E, Lopez-Otin C: Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Res. 1996;56(8):1746–1750.
   PubMed Web of Science ®Google Scholar
• Sleijfer S: Bleomycin-induced pneumonitis. Chest. 2001; 120(2):617–624.
   PubMed Web of Science ®Google Scholar
• Blum RH, Carter SK, Agre K: A clinical review of bleomycin—a new antineoplastic agent. Cancer. 1973;31(4):903–914.
   PubMed Web of Science ®Google Scholar
• Jones AW: Bleomycin lung damage: the pathology and nature of the lesion. Brit J Dis Chest. 1978;72(4):321–326.
   PubMedGoogle Scholar
• Bedrossian CW, Luna MA, Mackay B, Lichtiger B: Ultrastructure of pulmonary bleomycin toxicity. Cancer. 1973;32(1):44–51.
   PubMed Web of Science ®Google Scholar
• Simpson AB, Paul J, Graham J, Kaye SB: Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–95: a review of patients with germ cell tumours. Brit J Cancer. 1998;78(8):1061–1066.
   PubMed Web of Science ®Google Scholar
• Brown RF, Drawbaugh RB, Marrs TC: An investigation of possible models for the production of progressive pulmonary fibrosis in the rat. The effects of repeated intratracheal instillation of bleomycin. Toxicology. 1988;51(1):101–110.
   PubMed Web of Science ®Google Scholar
• Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, McMahon FB, et al.: Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(4):L442– L452.
   PubMed Web of Science ®Google Scholar
• Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al.: Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for “active” disease. PloS one. 2013;8(4):e59348.
   PubMed Web of Science ®Google Scholar
• Azuma A, Takahashi S, Nose M, Araki K, Araki M, Takahashi T, et al.: Role of E-selectin in bleomycin induced lung fibrosis in mice. Thorax. 2000;55(2):147–152.
   PubMed Web of Science ®Google Scholar
• Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R: Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111–119.
   PubMed Web of Science ®Google Scholar
• Manali ED, Moschos C, Triantafillidou C, Kotanidou A, Psallidas I, Karabela SP, et al.: Static and dynamic mechanics of the murine lung after intratracheal bleomycin. BMC Pulm Med. 2011;11:33.
   PubMedGoogle Scholar
• Selman M, Pardo A: Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res. 2002;3:3.
   PubMedGoogle Scholar
• Iyer SN, Hyde DM, Giri SN: Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000;24(5):477–491.
   PubMed Web of Science ®Google Scholar
• Rydell-Törmänen K, Andreasson K, Hesselstrand R, Risteli J, Heinegard D, Saxne T, et al.: Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis. Lab Invest J Tech Method Pathol. 2012;92(6):917–925.
   PubMed Web of Science ®Google Scholar
• Kumar RK, Watkins SG, Lykke AW: Pulmonary responses to bleomycin-induced injury: an immunomorphologic and electron microscopic study. Exp Pathol. 1985;28(1):33–43.
   PubMedGoogle Scholar
• Lee TH, Avraham H, Lee SH, Avraham S: Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem. 2002;277(12):10445–10451.
   PubMed Web of Science ®Google Scholar
• Mishra A, Doyle NA, Martin WJc: Bleomycin-mediated pulmonary toxicity: evidence for a p53-mediated response. Am J Respir Cell Mol Biol. 2000;22(5):543–549.
   PubMed Web of Science ®Google Scholar
• Kawamoto M, Fukuda Y: Cell proliferation during the process of bleomycin-induced pulmonary fibrosis in rats. Acta Pathol. Japonica. 1990;40(4):227–238.
   PubMedGoogle Scholar
• Sugahara K, Iyama K, Kuroda MJ, Sano K: Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. J Pathol. 1998;186(1):90–98.
   PubMed Web of Science ®Google Scholar
• Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD: Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol. 2000;279(1):L143–L151.
   PubMed Web of Science ®Google Scholar
• Adamson IY, Young L, Bowden DH: Relationship of alveolar epithelial injury and repair to the induction of pulmonary fibrosis. Am J Pathol. 1988;130(2):377–383.
   PubMed Web of Science ®Google Scholar
• Azuma A, Li YJ, Abe S, Usuki J, Matsuda K, Henmi S, et al.: Interferon-{beta} inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-{beta} and thrombospondin. Am J Respir Cell Mol Biol. 2005;32(2): 93–98.
   PubMed Web of Science ®Google Scholar
• Mutsaers SE, Foster ML, Chambers RC, Laurent GJ, McAnulty RJ: Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol. 1998;18(5):611–619.
   PubMed Web of Science ®Google Scholar
• Lama V, Moore BB, Christensen P, Toews GB, Peters-Golden M: Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol. 2002;27(6):752–758.
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A: Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thoracic Soc. 2006;3(4):364–372.
   PubMedGoogle Scholar
• Molina-Molina M, Serrano-Mollar A, Bulbena O, Fernandez-Zabalegui L, Closa D, Marin-Arguedas A, et al.: Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax. 2006;61(7):604–610.
   PubMed Web of Science ®Google Scholar
• Moore BB, Ballinger MN, White ES, Green ME, Herrygers AB, Wilke CA, et al.: Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J Immunol. 2005;174(9):5644–5649.
   PubMed Web of Science ®Google Scholar
• Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N: Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol. 1997;16(1):91–101.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD: Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol. 2003;284(3):L501–L507.
   PubMed Web of Science ®Google Scholar
• Wang R, Zagariya A, Ibarra-Sunga O, Gidea C, Ang E, Deshmukh S, et al.: Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. Am J Physiol. 1999;276(5 Pt 1):L885–L889.
   PubMed Web of Science ®Google Scholar
• Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, et al.: Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol. 1997;17(3):272–278.
   PubMed Web of Science ®Google Scholar
• Hagimoto N, Kuwano K, Inoshima I, Yoshimi M, Nakamura N, Fujita M, et al.: TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol. 2002;168(12):6470–6478.
   PubMed Web of Science ®Google Scholar
• Wang D, Morales JE, Calame DG, Alcorn JL, Wetsel RA: Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice. Mol Ther: J Am Soc Gene Ther. 2010;18(3):625–634.
   PubMed Web of Science ®Google Scholar
• Serrano-Mollar A, Nacher M, Gay-Jordi G, Closa D, Xaubet A, Bulbena O: Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2007;176(12):1261–1268.
   PubMed Web of Science ®Google Scholar
• Matute-Bello G, Frevert CW, Martin TR: Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008;295(3):L379–L399.
   PubMed Web of Science ®Google Scholar
• Adamson IY, Bowden DH: The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77(2):185–197.
   PubMed Web of Science ®Google Scholar
• Adamson IY, Bowden DH: Origin of ciliated alveolar epithelial cells in bleomycin-induced lung injury. Am J Pathol. 1977;87(3):569–580.
   PubMed Web of Science ®Google Scholar
• Adamson IY, Bowden DH: Bleomycin-induced injury and metaplasia of alveolar type 2 cells. Relationship of cellular responses to drug presence in the lung. Am J Pathol. 1979;96(2):531–544.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, et al.: Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest. 1999;104(1):13–19.
   PubMed Web of Science ®Google Scholar
• Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Matsuba T, et al.: Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J: Official J Eur Soc Clin Resp Physiol. 2001;17(2):180–189.
   Google Scholar
• Wang R, Ramos C, Joshi I, Zagariya A, Pardo A, Selman M, et al.: Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am J Physiol. 1999;277(6 Pt 1):L1158–L1164.
   PubMed Web of Science ®Google Scholar
• Uhal BD, Kim JK, Li X, Molina-Molina M: Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Design. 2007;13(12):1247–1256.
   PubMed Web of Science ®Google Scholar
• Molina-Molina M, Xaubet A, Li X, Abdul-Hafez A, Friderici K, Jernigan K, et al.: Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. Eur Respir J: Official J Eur Soc Clin Respir Physiol. 2008;32(4):1004–1008.
   PubMed Web of Science ®Google Scholar
• Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ: Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest. 2004;126(2):438–446.
   PubMed Web of Science ®Google Scholar
• King TE, Jr., Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–1961.
   PubMed Web of Science ®Google Scholar
• Khalil N, O'Connor RN, Flanders KC, Unruh H: TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am J Respir Cell Mol Biol. 1996;14(2):131–138.
   PubMed Web of Science ®Google Scholar
• Fujii M, Hayakawa H, Urano T, Sato A, Chida K, Nakamura H, et al.: Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res. 2000;99(2):111–117.
   PubMed Web of Science ®Google Scholar
• Uhal BD, Joshi I, True AL, Mundle S, Raza A, Pardo A, et al.: Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol. 1995;269(6 Pt 1):L819–L828.
   PubMed Web of Science ®Google Scholar
• Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL: Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol. 2001;54(2):132–138.
   PubMed Web of Science ®Google Scholar
• Song M, He B, Qiu Z: Expressions of TNF alpha, PDGF in alveolar type II epithelial cells of rats with bleomycin-induced pulmonary fibrosis. Zhonghua jie he he hu xi za zhi (Chinese J Tuberculosis Respir Dis.) 1998;21(4):221–223.
   PubMedGoogle Scholar
• Cavarra E, Carraro F, Fineschi S, Naldini A, Bartalesi B, Pucci A, et al.: Early response to bleomycin is characterized by different cytokine and cytokine receptor profiles in lungs. Am J Physiol Lung Cell Mol Physiol. 2004;287(6):L1186–L1192.
   PubMed Web of Science ®Google Scholar
• Aumiller V, Balsara N, Wilhelm J, Gunther A, Konigshoff M: WNT/beta-catenin signaling induces IL-1beta expression by alveolar epithelial cells in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013;49(1):96–104.
   PubMed Web of Science ®Google Scholar
• Everson MP, Chandler DB: Changes in distribution, morphology, and tumor necrosis factor-alpha secretion of alveolar macrophage subpopulations during the development of bleomycin-induced pulmonary fibrosis. Am J Pathol. 1992;140(2):503–512.
   PubMed Web of Science ®Google Scholar
• Sakanashi Y, Takeya M, Yoshimura T, Feng L, Morioka T, Takahashi K: Kinetics of macrophage subpopulations and expression of monocyte chemoattractant protein-1 (MCP-1) in bleomycin-induced lung injury of rats studied by a novel monoclonal antibody against rat MCP-1. J Leukocyte Biol. 1994;56(6):741–750.
   PubMed Web of Science ®Google Scholar
• Gasse P, Riteau N, Charron S, Girre S, Fick L, Petrilli V, et al.: Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med. 2009;179(10):903–913.
   PubMed Web of Science ®Google Scholar
• Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al.: Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med. 2011;184(5):569–581.
   PubMed Web of Science ®Google Scholar
• Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A: Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med. 1994;149(3 Pt 1):655–659.
   PubMed Web of Science ®Google Scholar
• Carre PC, Mortenson RL, King TE, Jr., Noble PW, Sable CL, Riches DW: Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest. 1991;88(6):1802–1810.
   PubMed Web of Science ®Google Scholar
• Standiford TJ, Rolfe MW, Kunkel SL, Lynch JP, 3rd, Burdick MD, Gilbert AR, et al.: Macrophage inflammatory protein-1 alpha expression in interstitial lung disease. J Immunol. 1993;151(5):2852–2863.
   PubMed Web of Science ®Google Scholar
• Schwartz DA, Helmers RA, Dayton CS, Merchant RK, Hunninghake GW: Determinants of bronchoalveolar lavage cellularity in idiopathic pulmonary fibrosis. J Appl Physiol. 1991;71(5):1688–1693.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN: Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol. 1993;150(9):4188–4196.
   PubMed Web of Science ®Google Scholar
• Furuie H, Yamasaki H, Suga M, Ando M: Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J: Official J Eur Soc Clin Respir Physiol. 1997;10(4):787–794.
   PubMed Web of Science ®Google Scholar
• Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y: Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol. 1993;143(3):651–655.
   PubMed Web of Science ®Google Scholar
• Pan LH, Ohtani H, Yamauchi K, Nagura H: Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int. 1996;46(2):91–99.
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, Phan SH: Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 1997;16(4):438–447.
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, Nozaki Y, Hatano K, Phan SH: Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. Cytokine. 2001;15(3):138–147.
   PubMed Web of Science ®Google Scholar
• Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170(3):655–663.
   PubMed Web of Science ®Google Scholar
• Vesey DA, Cheung C, Cuttle L, Endre Z, Gobe G, Johnson DW: Interleukin-1 beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-beta-dependent mechanism. J Lab Clin Med. 2002;140(5):342–350.
   PubMed Web of Science ®Google Scholar
• Tufvesson E, Westergren-Thorsson G: Alteration of proteoglycan synthesis in human lung fibroblasts induced by interleukin-1 beta and tumor necrosis factor-alpha. J Cell Biochem. 2000;77(2):298–309.
   PubMed Web of Science ®Google Scholar
• Solis-Herruzo JA, Brenner DA, Chojkier M: Tumor necrosis factor-alpha inhibits collagen gene-transcription and collagen-synthesis in cultured human-fibroblasts. J Biol Chem. 1988;263(12):5841–5845.
   PubMed Web of Science ®Google Scholar
• Siwik DA, Chang DLF, Colucci WS: Interleukin-1 beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res. 2000;86(12):1259–1265.
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor beta(1) gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996;271(30):17779–17784.
   PubMed Web of Science ®Google Scholar
• Moore BB, Peters-Golden M, Christensen PJ, Lama V, Kuziel WA, Paine R, et al.: Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2. Am J Physiol-Lung C. 2003;284(2):L342–L349.
   PubMed Web of Science ®Google Scholar
• Giri SN, Hyde DM, Nakashima JM: Analysis of bronchoalveolar lavage fluid from bleomycin-induced pulmonary fibrosis in hamsters. Toxicol Pathol. 1986;14(2):149–157.
   PubMedGoogle Scholar
• Helene M, Lake-Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM: T cell independence of bleomycin-induced pulmonary fibrosis. J Leukocyte Biol. 1999;65(2):187–195.
   PubMed Web of Science ®Google Scholar
• Izumo T, Kondo M, Nagai A: Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis. Eur Respir J: Official J Eur Soc Clin Respir Physiol. 2009;34(6):1444–1451.
   PubMed Web of Science ®Google Scholar
• Okuma T, Terasaki Y, Kaikita K, Kobayashi H, Kuziel WA, Kawasuji M, et al.: C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol. 2004;204(5):594–604.
   PubMed Web of Science ®Google Scholar
• Kim JY, Choeng HC, Ahn C, Cho SH: Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis. Yonsei Med J. 2009;50(1):68–77.
   PubMed Web of Science ®Google Scholar
• Baer M, Dillner A, Schwartz RC, Sedon C, Nedospasov S, Johnson PF: Tumor necrosis factor alpha transcription in macrophages is attenuated by an autocrine factor that preferentially induces NF-kappa B p50. Mol Cell Biol. 1998;18(10):5678–5689.
   PubMed Web of Science ®Google Scholar
• Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, et al.: IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest. 2007;117(12):3786–3799.
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, McGarry B, Lukacs N, Huffnagle G, Egan RW, Phan SH: The role of IL-5 in bleomycin-induced pulmonary fibrosis. J Leukocyte Biol. 1998;64(5):657–666.
   PubMed Web of Science ®Google Scholar
• Hao H, Cohen DA, Jennings CD, Bryson JS, Kaplan AM: Bleomycin-induced pulmonary fibrosis is independent of eosinophils. J Leukocyte Biol. 2000;68(4):515–521.
   PubMed Web of Science ®Google Scholar
• Schrier DJ, Phan SH, Mcgarry BM: The effects of the nude (Nu Nu) mutation on bleomycin-induced pulmonary fibrosis - a biochemical evaluation. Am Rev Respir Dis. 1983;127(5):614–617.
   PubMed Web of Science ®Google Scholar
• Boomars KA, Schweizer RC, Zanen P, van den Bosch JMM, Lammers JWJ, Koenderman L: Eosinophil chemotactic activity in bronchoalveolar lavage from idiopathic pulmonary fibrosis is dependent on cytokine priming of eosinophils. Eur Respir J. 1998;11(5):1009–1014.
   PubMed Web of Science ®Google Scholar
• Yasuoka S, Nakayama T, Kawano T, Ogushi F, Doi H, Hayashi H, et al.: Comparison of cell profiles of bronchial and bronchoalveolar lavage fluids between normal subjects and patients with idiopathic pulmonary fibrosis. Tohoku J Exp Med. 1985;146(1):33–45.
   PubMed Web of Science ®Google Scholar
• Peterson MW, Monick M, Hunninghake GW: Prognostic role of eosinophils in pulmonary fibrosis. Chest. 1987;92(1):51–56.
   PubMed Web of Science ®Google Scholar
• Haslam PL, Turton CWG, Lukoszek A, Salsbury AJ, Dewar A, Collins JV, et al.: Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax. 1980;35(5):328–339.
   PubMed Web of Science ®Google Scholar
• Reynolds HY, Fulmer JD, Kazmierowski JA, Roberts WC, Frank MM, Crystal RG: Analysis of cellular and protein-content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest. 1977;59(1):165–175.
   PubMed Web of Science ®Google Scholar
• Daniil Z, Kitsanta P, Kapotsis G, Mathioudaki M, Kollintza A, Karatza M, et al.: CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis. Respir Res. 2005;6.
   PubMed Web of Science ®Google Scholar
• Obayashi Y, Yamadori I, Fujita J, Yoshinouchi T, Ueda N, Takahara J: The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest. 1997;112(5):1338–1343.
   PubMed Web of Science ®Google Scholar
• Tabuena RP, Nagai S, Tsutsumi T, Handa T, Minoru T, Mikuniya T, et al.: Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese patients. Respiration. 2005;72(5):490–498.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Kawanami O, Ferrans VJ, Young RC, Jr., Roberts WC, Crystal RG: Characterization of the inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Respir Dis. 1981;123(4 Pt 1):407–412.
   PubMed Web of Science ®Google Scholar
• Kradin RL, Divertie MB, Colvin RB, Ramirez J, Ryu J, Carpenter HA, et al.: Usual interstitial pneumonitis is a T-cell alveolitis. Clin Immunol Immunopathol. 1986;40(2):224–235.
   PubMedGoogle Scholar
• Selman M, Gonzalez G, Bravo M, Sullivan-Lopez J, Ramos C, Montano M, et al.: Effect of lung T lymphocytes on fibroblasts in idiopathic pulmonary fibrosis and extrinsic allergic alveolitis. Thorax. 1990;45(6):451–455.
   PubMed Web of Science ®Google Scholar
• Papiris SA, Kollintza A, Karatza M, Manali ED, Sotiropoulou C, Milic-Emili J, et al.: CD8 +T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis. J Inflamm. 2007;4:14.
   Google Scholar
• Papiris SA, Kollintza A, Kitsanta P, Kapotsis G, Karatza M, Milic-Emili J, et al.: Relationship of BAL and lung tissue CD4+ and CD8+ T lymphocytes, and their ratio in idiopathic pulmonary fibrosis. Chest. 2005;128(4):2971–2977.
   PubMed Web of Science ®Google Scholar
• Campbell DA, Poulter LW, Janossy G, du Bois RM: Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax. 1985;40(6):405–411.
   PubMed Web of Science ®Google Scholar
• Wallace WA, Howie SE, Krajewski AS, Lamb D: The immunological architecture of B-lymphocyte aggregates in cryptogenic fibrosing alveolitis. J Pathol. 1996;178(3):323–329.
   PubMed Web of Science ®Google Scholar
• Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csizmadia E, et al.: Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol. 2013;191(5):2089–2095.
   PubMed Web of Science ®Google Scholar
• Schwartz MI, Dreisin RB, Pratt DS, Stanford RE: Immunofluorescent patterns in the idiopathic interstitial pneumonias. J Lab Clin Med. 1978;91(6):929–938.
   PubMedGoogle Scholar
• Wallace WA, Schofield JA, Lamb D, Howie SE: Localisation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis. Thorax. 1994;49(11):1139–1145.
   PubMed Web of Science ®Google Scholar
• Matsuse T, Teramoto S, Katayama H, Sudo E, Ekimoto H, Mitsuhashi H, et al.: ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury. Eur Respir J: Official J Eur Soc Clin Respir Physiol. 1999;13(1):71–77.
   PubMed Web of Science ®Google Scholar
• Williams AE, Chambers RC: The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014;306(3):L217–L230.
   PubMed Web of Science ®Google Scholar
• Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122(1):103–111.
   PubMed Web of Science ®Google Scholar
• Cutroneo KR, White SL, Phan SH, Ehrlich HP: Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J Cell Physiol. 2007;211(3):585–589.
   PubMed Web of Science ®Google Scholar
• Hu B, Wu Z, Phan SH: Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol. 2003;29(3):397–404.
   PubMed Web of Science ®Google Scholar
• Ponticos M, Holmes AM, Xu SW, Leoni P, Khan K, Rajkumar VS, et al.: Pivotal role of connective tissue growth factor in lung fibrosis MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009;60(7):2142–2155.
   PubMed Web of Science ®Google Scholar
• Annes JP, Chen Y, Munger JS, Rifkin DB: Integrin alpha(v)beta(6)-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol. 2004;165(5):723–734.
   PubMed Web of Science ®Google Scholar
• Schultz-Cherry S, Murphy-Ullrich JE: Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol. 1993;122(4):923–932.
   PubMed Web of Science ®Google Scholar
• Grotendorst GR, Duncan MR: Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J: Official Pub Federat Am Soc Exp Biol. 2005;19(7):729–738.
   PubMed Web of Science ®Google Scholar
• Grotendorst GR, Rahmanie H, Duncan MR: Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J: Official Publ Federat Am Soc Exp Biol. 2004;18(3):469–479.
   PubMed Web of Science ®Google Scholar
• Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, et al.: Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J: Official Publ Federat Am Soc Exp Biol. 1999;13(13):1774–1786.
   PubMed Web of Science ®Google Scholar
• Kothapalli D, Frazier KS, Welply A, Segarini PR, Grotendorst GR: Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ: Mol Biol J Am Assoc Cancer Res. 1997;8(1):61–68.
   PubMed Web of Science ®Google Scholar
• Vyalov SL, Gabbiani G, Kapanci Y: Rat alveolar myofibroblasts acquire alpha-smooth muscle actin expression during bleomycin-induced pulmonary fibrosis. Am J Pathol. 1993;143(6):1754–1765.
   PubMed Web of Science ®Google Scholar
• Coker RK, Laurent GJ, Shahzeidi S, Lympany PA, du Bois RM, Jeffery PK, et al.: Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol. 1997;150(3):981–991.
   PubMed Web of Science ®Google Scholar
• Santana A, Saxena B, Noble NA, Gold LI, Marshall BC: Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 1995;13(1):34–44.
   PubMed Web of Science ®Google Scholar
• Nakagome K, Dohi M, Okunishi K, Tanaka R, Miyazaki J, Yamamoto K: In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax. 2006;61(10):886–894.
   PubMed Web of Science ®Google Scholar
• Khalil N, Bereznay O, Sporn M, Greenberg AH: Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med. 1989;170(3):727–737.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114(9):1308–1316.
   PubMed Web of Science ®Google Scholar
• Kurotani R, Okumura S, Matsubara T, Yokoyama U, Buckley JR, Tomita T, et al.: Secretoglobin 3A2 suppresses bleomycin-induced pulmonary fibrosis by transforming growth factor beta signaling down-regulation. J Biol Chem. 2011;286(22):19682–19692.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang Y, Hyde DM, Gotwals PJ, Koteliansky VE, Ryan ST, et al.: Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax. 1999;54(9):805–812.
   PubMed Web of Science ®Google Scholar
• Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj JI, Borras-Cuesta F, Lasarte JJ, et al.: Therapeutic effect of a peptide inhibitor of TGF-beta on pulmonary fibrosis. Cytokine. 2011;53(3):327–333.
   PubMed Web of Science ®Google Scholar
• Russo RC, Guabiraba R, Garcia CC, Barcelos LS, Roffe E, Souza AL, et al.: Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol. 2009;40(4):410–421.
   PubMed Web of Science ®Google Scholar
• Atzori L, Chua F, Dunsmore SE, Willis D, Barbarisi M, McAnulty RJ, et al.: Attenuation of bleomycin induced pulmonary fibrosis in mice using the heme oxygenase inhibitor Zn-deuteroporphyrin IX-2,4-bisethylene glycol. Thorax. 2004;59(3):217–223.
   PubMed Web of Science ®Google Scholar
• Yehualaeshet T, O'Connor R, Green-Johnson J, Mai S, Silverstein R, Murphy-Ullrich JE, et al.: Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol. 1999;155(3):841–851.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lu HP, Lai GX: A preliminary study of CTGF in bleomycin-induced mouse pulmonary fibrosis. Xi Bao yu fen zi mian yi xue za zhi (Chinese J Cell Mol Immunol.) 2005;21(3):290–292.
   PubMedGoogle Scholar
• Datta A, Scotton CJ, Chambers RC: Novel therapeutic approaches for pulmonary fibrosis. Brit J Pharmacol. 2011;163(1):141–172.
   PubMed Web of Science ®Google Scholar
• Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, et al.: Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 1991;5(2):155–162.
   PubMed Web of Science ®Google Scholar
• Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G: Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med. 1995;152(6 Pt 1):2163–2169.
   PubMed Web of Science ®Google Scholar
• Hiwatari N, Shimura S, Yamauchi K, Nara M, Hida W, Shirato K: Significance of elevated procollagen-III-peptide and transforming growth factor-beta levels of bronchoalveolar lavage fluids from idiopathic pulmonary fibrosis patients. Tohoku J Exp Med. 1997;181(2):285–295.
   PubMed Web of Science ®Google Scholar
• Khalil N, Parekh TV, O'Connor R, Antman N, Kepron W, Yehaulaeshet T, et al.: Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis. Thorax. 2001;56(12):907– 915.
   PubMed Web of Science ®Google Scholar
• Tatler AL, Saini G, Goodwin A, Gbolohan O, Clifford RL, Al'Hourani M, et al.: Transcriptional Mechanisms Regulating Expression of the Avb6 Integrin in Ipf. Thorax. 2012;67:A34–A35.
   Web of Science ®Google Scholar
• John AE, Luckett JC, Tatler AL, Awais RO, Desai A, Habgood A, et al.: Preclinical SPECT/CT imaging of alphavbeta6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med: Official Publ, Soc Nucl Med. 2013;54(12):2146–2152.
   PubMed Web of Science ®Google Scholar
• Reibman J, Meixler S, Lee TC, Gold LI, Cronstein BN, Haines KA, et al.: Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci USA. 1991;88(15):6805–6809.
   PubMed Web of Science ®Google Scholar
• Khalil N, O'Connor RN, Flanders KC, Shing W, Whitman CI: Regulation of type II alveolar epithelial cell proliferation by TGF-beta during bleomycin-induced lung injury in rats. Am J Physiol. 1994;267(5 Pt 1):L498–L507.
   PubMed Web of Science ®Google Scholar
• Zhang F, Nielsen LD, Lucas JJ, Mason RJ: Transforming growth factor-beta antagonizes alveolar type II cell proliferation induced by keratinocyte growth factor. Am J Respir Cell Mol Biol. 2004;31(6):679–686.
   PubMed Web of Science ®Google Scholar
• Yue J, Mulder KM: Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Therapeut. 2001;91(1):1–34.
   PubMed Web of Science ®Google Scholar
• Park SH, Saleh D, Giaid A, Michel RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997;156(2 Pt 1):600–608.
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Hollinger MA, Giri SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276(2 Pt 1):L311–L318.
   PubMed Web of Science ®Google Scholar
• Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15(4):255–273.
   PubMed Web of Science ®Google Scholar
• Bergmann M, Tiroke A, Schafer H, Barth J, Haverich A: Gene expression of profibrotic mediators in bronchiolitis obliterans syndrome after lung transplantation. Scand Cardiovasc J: SCJ. 1998;32(2):97–103.
   PubMed Web of Science ®Google Scholar
• Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M, et al.: Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest. 1990;86(4):1055–1064.
   PubMed Web of Science ®Google Scholar
• Nagaoka I, Trapnell BC, Crystal RG: Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. J Clin Invest. 1990;85(6):2023–2027.
   PubMed Web of Science ®Google Scholar
• Martinet Y, Rom WN, Grotendorst GR, Martin GR, Crystal RG: Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med. 1987;317(4):202–209.
   PubMed Web of Science ®Google Scholar
• Fonseca C, Abraham D, Renzoni EA: Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;44(1): 1–10.
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Dawes KE, Shock A, Gray AJ, Reeves JT, Laurent GJ: Endothelin-1 and Endothelin-3 induce chemotaxis and replication of pulmonary-artery fibroblasts. Am J Respir Cell Mol Biol. 1992;7(5):492–499.
   PubMed Web of Science ®Google Scholar
• Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, et al.: Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum. 2007;56(12):4189–4194.
   PubMed Web of Science ®Google Scholar
• Ross B, D'Orleans-Juste P, Giaid A: Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic. Am J Respir Cell Mol Biol. 2010;42(1):16–20.
   PubMed Web of Science ®Google Scholar
• Saleh D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa M, et al.: Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol. 1997;16(2):187–193.
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J: Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung. 2001;179(3):163–174.
   PubMed Web of Science ®Google Scholar
• King TE, Jr., Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al.: BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92–99.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Gharaee-Kermani M, Zhang K, Karmiol S, Phan SH: Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis. Am J Pathol. 1996;148(2):527–537.
   PubMed Web of Science ®Google Scholar
• Zhang K, Rekhter MD, Gordon D, Phan SH: Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol. 1994;145(1):114–125.
   PubMed Web of Science ®Google Scholar
• Phan SH. The myofibroblast in pulmonary fibrosis. Chest. 2002;122(6 Suppl):286S–289S.
   PubMed Web of Science ®Google Scholar
• Zhang K, Flanders KC, Phan SH: Cellular localization of transforming growth factor-beta expression in bleomycin-induced pulmonary fibrosis. Am J Pathol. 1995;147(2):352–361.
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Chambers RC: Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132(4):1311–1321.
   PubMed Web of Science ®Google Scholar
• Pardo A, Selman M: Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell B. 2002;34(12):1534–1538.
   PubMed Web of Science ®Google Scholar
• Kuhn C, McDonald JA: The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol. 1991;138(5):1257–1265.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Horowitz JC: Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thoracic Soc. 2006;3(4):350–356.
   PubMedGoogle Scholar
• Vuga LJ, Ben-Yehudah A, Kovkarova-Naumovski E, Oriss T, Gibson KF, Feghali-Bostwick C, et al.: WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol. 2009;41(5):583–589.
   PubMed Web of Science ®Google Scholar
• Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, Armendariz-Borunda J: The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3:16.
   PubMedGoogle Scholar
• Jenkins G: Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis. Thorax. 2013;68(7):603–605.
   PubMed Web of Science ®Google Scholar
• Fleischman RW, Baker JR, Thompson GR, Schaeppi UH, Illievski VR, Cooney DA, et al.: Bleomycin-induced interstitial pneumonia in dogs. Thorax. 1971;26(6):675–682.
   PubMed Web of Science ®Google Scholar
• Hagiwara SI, Ishii Y, Kitamura S: Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med. 2000;162(1):225–231.
   PubMed Web of Science ®Google Scholar
• Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al.: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2013;110(9):3507–3512.
   PubMed Web of Science ®Google Scholar